Fabrication and statistical optimization of surface engineered PLGA nanoparticles for naso-brain delivery of ropinirole hydrochloride: In-vitro-ex-vivo studies

Journal of Biomaterials Science, Polymer Edition

Volumn 24, Issue 15, 2013, Pages 1740-1756

  Patil, Ganesh B ^a   Surana, Sanjay J ^a  

^a R C PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

biodegradable polymer; brain targeting; hepatic metabolism; naso brain delivery; surface modification; vitamin E TPGS

Indexed keywords

BIODEGRADABLE NANOPARTICLE; BRAIN TARGETING; HEPATIC METABOLISMS; NASO-BRAIN DELIVERY; POLY(LACTIC-CO-GLYCOLIC ACID); STATISTICAL OPTIMIZATION; TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATES; VITAMIN E TPGS;

BIOCHEMISTRY; BIODEGRADABLE POLYMERS; COPOLYMERS; DIFFERENTIAL SCANNING CALORIMETRY; EMULSIFICATION; METABOLISM; NANOPARTICLES; PHYSIOLOGY; SURFACE TREATMENT;

OPTIMIZATION;

ALPHA TOCOPHEROL; CRYOPROTECTIVE AGENT; NANOPARTICLE; POLYGLACTIN; ROPINIROLE; TOCOFERSOLAN;

ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CHEMICAL INTERACTION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG RELEASE; FACTORIAL DESIGN; FIRST PASS EFFECT; FREEZE DRYING; HISTOPATHOLOGY; HUMIDITY; NONHUMAN; NOSE MUCOSA; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL;

NASO;

ANIMALS; BRAIN; CALORIMETRY, DIFFERENTIAL SCANNING; CENTRAL NERVOUS SYSTEM DISEASES; DOPAMINE AGONISTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HISTOCYTOCHEMISTRY; INDOLES; LACTIC ACID; NANOPARTICLES; NASAL MUCOSA; PARTICLE SIZE; POLYGLYCOLIC ACID; SHEEP; SURFACE PROPERTIES;

EID: 84884588193     PISSN: 09205063     EISSN: 15685624     Source Type: Journal    
DOI: 10.1080/09205063.2013.798880     Document Type: Article

References (43)

1. Shadab AP, Zeenat IZ, Syed MA, Sushma T, Divya V, Gaurav KJ, Azeem A, Nitin J, Jigar L, Khar RK, Ahmad FJ. CNS drug delivery systems: Novel approaches. Recent Pat. Drug Deliv. Formul. 2009;3:71-89
2. Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today. 1996;2:106-113
3. Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-To-brain delivery: In vitro and in vivo studies. Acta Biomater. 2011;7:4169-4176
4. Partridge WM. CNS drug design based on principles of blood-brain barrier transport. J. Neurochem. 1998;70:1781-1792
5. Johnson MD, Chen J, Anderson BD. Investigation of the mechanism of enhancement of central nervous system delivery of 20-beta-fluoro-20, 30-Dideoxyinosine via a blood-brain barrier adenosine deaminase-Activated prodrug. Drug Metab. Dispos. 2002;30:191-198
6. Lu W, Zhang Y, Tan YZ, Hu KL, Jiang XG, Fu SK. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J. Controlled Release. 2005;107:428-448
7. Jalali N, Moztarzadeh F, Mozafari M, Asgari S, Motevalian M, Alhosseini SN. Surface modification of poly (lactide-co-glycolide) nanoparticles by d-Tocopheryl polyethylene glycol 1000 succinate as potential carrier for the delivery of drugs to the brain. Colloids Surf., A. 2011;392:335-342
8. Hanson LR, Frey WH, 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9:S5
9. Hanson LR, Roeytenberg A, Martinez PM, Coppes VG, Sweet DC, Rao RJ, Marti DL, Hoekman JD, Matthews RB, Frey WH, 2nd, Panter SS. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J. Pharmacol. Exp. Ther. 2009;330:679-686
10. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey WH, 2nd, Deen DF. New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol. 2008;10:112-120
11. Liu XF, Fawcett JR, Hanson LR, Frey WH, 2nd. The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. J. Stroke Cerebrovasc. Dis. 2004;13:16-23
12. Kissel T, Werner U. Nasal delivery of peptides: An in vitro cell culture model for the investigation of transport and metabolism in human nasal epithelium. J. Control Release. 1998;53:195-203
13. Frey WH, 2nd. Bypassing the blood-brain barrier to delivery therapeutic agents to the brain and spinal cord. Drug Delivery Technol. 2002;2:46-49
14. Dhanda DS, Frey WH, 2nd, Leopold D, Kompella UB. Approaches for drug deposition in the human olfactory epithelium. Drug Delivery Technol. 2005;5:64-72
15. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: Physicochemical and therapeutic aspects. Int. J. Pharm. 2007;337:1-24
16. Belgamwar VS, Patel HS, Joshi AS, Agrawal A, Surana SJ, Tekade AR. Design and development of nasal mucoadhesive microspheres containing tramadol HCl for CNS targeting. Drug Delivery. 2011;18:353-360
17. Mistrya A, Stolnika S, Illum L. Nanoparticles for direct nose-To-brain delivery of drugs. Int. J. Pharm. 2009;379:146-157
18. Ali J, Ali M, Baboota S, Sahni JK, Ramassamy C, Dao L, Bhavna. Potential of nanoparticulate drug delivery systems by intranasal administration. Curr. Pharm. Des. 2010;16:1644-1653
19. Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A, Mallikarjuana NN, Manohar S, Liang HF, Kulkarni AR, Sung HW, Sairam M, Aminabhavi TM. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J. Control Release. 2005;108:193-214
20. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf., B. 2010;75:1-18
21. Couvreur P, Kante B, Roland M, Guiot P, Bauduin P, Speiser P. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: Preparation, morphological and sorptive properties. J. Pharm. Pharmacol. 1979;31:331-332
22. Krauland AH, Bernkop-Schnurch A. Thiomers: Development and in vitro evaluation of a peroral microparticulate peptide delivery system. Eur. J. Pharm. Biopharm. 2004;57:181-187
23. Prokop A, Davidson JM. Nanovehicular intracellular delivery systems. J. Pharm. Sci. 2008;97:3518-3590
24. Vert M, Mauduit J, Li S. Biodegradation of PLA/GA polymers: Increasing complexity. Biomaterials. 1994;15:1209-1213
25. Park K. Controlled drug delivery: Challenges and strategies. Washington (DC): American Chemical Society; 1997
26. Lu Z, Bei J, Wang S. A method for the preparation of polymeric nanocapsules without stabilizer. J. Control Release. 1999;61:107-112
27. Eastman Chemical Company. Vitamin E TPGS NF, Properties and applications., Kingsport, TN: Publication EFC-226A, October 1998
28. Fariss MW, Zhang JG. Vitamin E therapy in Parkinson's disease. Toxicology. 2003;189:129-146
29. Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf., B. 2010;81:412-421
30. Lalani J, Rathi M, Lalan M, Misra A. Protein functionalized tramadol-loaded PLGA nanoparticles: Preparation, optimization, stability a pharmacodynamic studies. Drug Dev. Ind. Pharm. Forthcoming 2012
31. Zhang X, Liu J, Qiao H, Liu H, Ni J, Zhang W, Shi Y. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol. 2010;197:120-128
32. Kumar VV, Chandrasekar D, Ramakrishna S, Kishan V, Rao YM, Diwan PV. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: Influence of wax and glyceride lipids on plasma pharmacokinetics. Int. J. Pharm. 2007;335:167-175
33. Varshosaz J, Tabbakhian M, Mohammadi MY. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J. Liposome Res. 2010;20:286-296
34. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Controlled Release. 1999;59:299-307
35. Pardeshi CV, Rajput PV, Belgamwar VS, Tekade AR. Formulation, optimization and evaluation of spray-Dried mucoadhesive microspheres as intranasal carriers for Valsartan. J. Microencapsulation. 2012;29:103-114
36. Mahajan HS, Gattani SG. Nasal administration of ondansetron using a novel microspheres delivery system. Pharm. Dev. Technol. 2009;14:226-232
37. Aji Alex MR, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur. J. Pharm. Sci. 2011;42:11-18
38. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D, L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Controlled Release. 2002;82:105-114
39. Mu L, Feng SS. PLGA/TPGS nanoparticles for controlled release of paclitaxel: Effects of the emulsifier and drug loading ratio. Pharm. Res. 2003;20:1864-1872
40. Feng S, Huang G. Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J. Controlled Release. 2001;71:53-69
41. Guerrero DQ, Fessi H, All'emann E, Doelker E. Influence of stabilizing agents and preparatives variables on the formation of poly (d, l-lactic acid) nanoparticles by an emulsificationdiffusion technique. Int. J. Pharm. 1996;143:133-141
42. Chacon M, Molpeceres J, Berges L, Guzman M, Aberturas MR. Stability and freeze-Drying of cyclosporine loaded poly (D, L lactide-glycolide) carriers. Eur. J. Pharm. Sci. 1999;8:99-107
43. Lamprecht A, Ubrich N, Hombreiro Pérez M, Lehr C, Hoffman M, Maincent P. Influences of process parameters on nanoparticles preparation performed by a double emulsion pressure homogenization technique. Int. J. Pharm. 2000;196:177-182